Gregory A. Newby,Jonathan S. Yen,Kaitly J. Woodard,Thiyagaraj Mayuranathan,Cicera R. Lazzarotto,Yichao Li,Heather Sheppard-Tillman,Shaina N. Porter,Yu Yao,Kalin Mayberry,Kelcee A. Everette,Yoonjeong Jang,Christopher J. Podracky,Elizabeth Thaman,Christophe Lechauve,Akshay Sharma,Jordana M. Henderson,Michelle F. Richter,Kevin T. Zhao,Shannon M. Miller,Tina Wang,Luke W. Koblan,Anton P. McCaffrey,John F. Tisdale,Theodosia A. Kalfa,Shondra M. Pruett-Miller,Shengdar Q. Tsai,Mitchell J. Weiss,David R. Liu

Abstract:Sickle cell disease (SCD) is caused by a mutation in the β-globin gene HBB<a href="/articles/s41586-021-03609-w#ref-CR1">1</a>. We used a custom adenine base editor (ABE8e-NRCH)<a href="/articles/s41586-021-03609-w#ref-CR2">2</a>,<a href="/articles/s41586-021-03609-w#ref-CR3">3</a> to convert the SCD allele (HBBS) into Makassar β-globin (HBBG), a non-pathogenic variant<a href="/articles/s41586-021-03609-w#ref-CR4">4</a>,<a href="/articles/s41586-021-03609-w#ref-CR5">5</a>. Ex vivo delivery of mRNA encoding the base editor with a targeting guide RNA into haematopoietic stem and progenitor cells (HSPCs) from patients with SCD resulted in 80% conversion of HBBS to HBBG. Sixteen weeks after transplantation of edited human HSPCs into immunodeficient mice, the frequency of HBBG was 68% and hypoxia-induced sickling of bone marrow reticulocytes had decreased fivefold, indicating durable gene editing. To assess the physiological effects of HBBS base editing, we delivered ABE8e-NRCH and guide RNA into HSPCs from a humanized SCD mouse<a href="/articles/s41586-021-03609-w#ref-CR6">6</a> and then transplanted these cells into irradiated mice. After sixteen weeks, Makassar β-globin represented 79% of β-globin protein in blood, and hypoxia-induced sickling was reduced threefold. Mice that received base-edited HSPCs showed near-normal haematological parameters and reduced splenic pathology compared to mice that received unedited cells. Secondary transplantation of edited bone marrow confirmed that the gene editing was durable in long-term haematopoietic stem cells and showed that HBBS-to-HBBG editing of 20% or more is sufficient for phenotypic rescue. Base editing of human HSPCs avoided the p53 activation and larger deletions that have been observed following Cas9 nuclease treatment. These findings point towards a one-time autologous treatment for SCD that eliminates pathogenic HBBS, generates benign HBBG, and minimizes the undesired consequences of double-strand DNA breaks.

Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease.

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model

Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells

Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction

Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology

Use of genome-editing tools to treat sickle cell disease

Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Cellular Function Reinstitution of Offspring Red Blood Cells Cloned from the Sickle Cell Disease Patient Blood Post CRISPR Genome Editing.

A simplified, G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 cell therapy to induce fetal hemoglobin for sickle cell disease

Base editing of haematopoietic stem cells rescues sickle cell disease in mice

Efficient Repair of Human Genetic Defect by CRISPR/Cas9-mediated Interlocus Gene Conversion

Highly efficient therapeutic gene editing of human hematopoietic stem cells

One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system